Table 1.
Cohort Name | Used in this study in: | Numbers of individuals | Original Reference |
---|---|---|---|
Sydney PCR cohort | Figures 2, 3, 4, 5, 6, 7, 9 | n=39 untreated MS n=40 healthy controls |
[1] |
Miami cohort | Figures 3, 6, 7 | n=73 untreated MS n=32 healthy controls |
[1] |
Treated MS cohort | Figure 10 |
Total, n=78: n=10, glatiramer acetate n=18, fingolimod n=20, interferon beta n=23, natalizumab n=7, dimethyl fumarate |
[8] |
ANZgene (microarray) cohort | Figures 1B, 6, 7 | n=99 untreated MS; n=45 healthy controls |
[2] |
Sydney RNASeq cohort | Figures 1, 3, 6, 7, Supplementary Figure. 1 and 2 | n=32 untreated MS; n=40 healthy controls |
[4] |
CIS cohort | Figure 1B | n=42 CIS | [3] |